title: HLA-A*26 and susceptility of iranian patients with non-Hodgkin lymphoma.
abstract: BACKGROUND
  Non-Hodgkin lymphoma (NHL) includes a wide range of diseases with different clinical and biological features. NHL is usually presented as localized or generalized lymphadenopathy. It has been suggested that the HLA class I and II are associated with susceptibility to NHL. Different ethnic groups have been found to have different HLA class I and II alleles which affect NHL.
  
  
  OBJECTIVE
  To evaluate the association of HLA class I and class II with Non-Hodgkin's lymphoma in Iranian patients.
  
  
  METHODS
  We performed a case-control genotyping study on 75 Iranian NHL patients who were selected from among the patients referred to the Bone Marrow Transplantation Department of Taleghani Hospital and 120 apparently healthy control subjects using the SSP-PCR by a commercial kit.
  
  
  RESULTS
  Our results demonstrated that the HLA-A*26 (p: 0.026; OR: 8.5) and HLA-B*35 (p: 0.022; OR: 0.375) alleles had positive and negative associations with NHL disease, respectively. HLA-DRB1*13 allele showed decrease of frequency in patients in comparison with the controls, but it did not remain significant after correction.
  
  
  CONCLUSIONS
  Our results conclude that HLA-A*26 may represent as a genetic susceptibility factors in Iranian patients with Non-Hodgkin's lymphoma, a finding which generally supports contribution of genetic factors in the etiology of this disorder. In addition, these results may be useful in designing a peptide based vaccine for the Iranian NHL patients with HLA-A*26.
authors.affiliation: Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran, e-mail:ar.sayad@yahoo.com.
authors.forename: Arezou
authors.initials: A
authors.lastname: Sayad
authors.forename: Mohammad Taghi
authors.initials: MT
authors.lastname: Akbari
authors.forename: Mahshid
authors.initials: M
authors.lastname: Mehdizadeh
authors.forename: Mohammad
authors.initials: M
authors.lastname: Taheri
authors.forename: Abbas
authors.initials: A
authors.lastname: Hajifathali
mesh_terms: D000328:Adult; D000483:Alleles; D019496:Cancer Vaccines; D016022:Case-Control Studies; D005260:Female; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D015234:HLA-A Antigens / Q000235:genetics*; D015797:HLA-B35 Antigen / Q000235:genetics; D006650:Histocompatibility Testing; D006801:Humans; D007492:Iran; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D055815:Young Adult
chemical_list: D019496:Cancer Vaccines; D015234:HLA-A Antigens; C039683:HLA-A*26 antigen; C500431:HLA-B*35:01 antigen; D015797:HLA-B35 Antigen